| The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes G Gaich, JY Chien, H Fu, LC Glass, MA Deeg, WL Holland, ... Cell metabolism 18 (3), 333-340, 2013 | 984 | 2013 |
| Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio K Pak, H Uno, DH Kim, L Tian, RC Kane, M Takeuchi, H Fu, B Claggett, ... JAMA oncology 3 (12), 1692-1696, 2017 | 228 | 2017 |
| Alternatives to hazard ratios for comparing the efficacy or safety of therapies in noninferiority studies H Uno, J Wittes, H Fu, SD Solomon, B Claggett, L Tian, T Cai, MA Pfeffer, ... Annals of internal medicine 163 (2), 127-134, 2015 | 213 | 2015 |
| Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12-and 24-week phase 2 studies CM Kazda, Y Ding, RP Kelly, P Garhyan, C Shi, CN Lim, H Fu, DE Watson, ... Diabetes Care 39 (7), 1241-1249, 2016 | 182 | 2016 |
| Short‐term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes RP Kelly, P Garhyan, E Raddad, H Fu, CN Lim, MJ Prince, JA Pinaire, ... Diabetes, Obesity and Metabolism 17 (4), 414-422, 2015 | 108 | 2015 |
| Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations L Tian, H Fu, SJ Ruberg, H Uno, LJ Wei Biometrics 74 (2), 694-702, 2018 | 81 | 2018 |
| Multi-armed angle-based direct learning for estimating optimal individualized treatment rules with various outcomes Z Qi, D Liu, H Fu, Y Liu Journal of the American Statistical Association 115 (530), 678-691, 2020 | 74 | 2020 |
| Learning optimal personalized treatment rules in consideration of benefit and risk: with an application to treating type 2 diabetes patients with insulin therapies Y Wang, H Fu, D Zeng Journal of the American Statistical Association 113 (521), 1-13, 2018 | 69 | 2018 |
| Estimating optimal treatment regimes via subgroup identification in randomized control trials and observational studies H Fu, J Zhou, DE Faries Statistics in medicine 35 (19), 3285-3302, 2016 | 63 | 2016 |
| Evaluating and utilizing probability of study success in clinical development Y Wang, H Fu, P Kulkarni, C Kaiser Clinical Trials 10 (3), 407-413, 2013 | 62 | 2013 |
| Identification of subgroups with differential treatment effects for longitudinal and multiresponse variables WY Loh, H Fu, M Man, V Champion, M Yu Statistics in medicine 35 (26), 4837-4855, 2016 | 47 | 2016 |
| Detecting outlying trials in network meta‐analysis J Zhang, H Fu, BP Carlin Statistics in medicine 34 (19), 2695-2707, 2015 | 47 | 2015 |
| Identifying factors associated with hypoglycemia-related hospitalizations among elderly patients with T2DM in the US: a novel approach using influential variable analysis H Fu, W Xie, B Curtis, D Schuster Current medical research and opinion 30 (9), 1787-1793, 2014 | 45 | 2014 |
| Factors associated with clopidogrel use, adherence, and persistence in patients with acute coronary syndromes undergoing percutaneous coronary intervention B Zhu, Z Zhao, P McCollam, J Anderson, JP Bae, H Fu, M Zettler, ... Current medical research and opinion 27 (3), 633-641, 2011 | 45 | 2011 |
| Guidance on the implementation and reporting of a drug safety Bayesian network meta‐analysis D Ohlssen, KL Price, H Amy Xia, H Hong, J Kerman, H Fu, G Quartey, ... Pharmaceutical Statistics 13 (1), 55-70, 2014 | 44 | 2014 |
| Impact of out-of-pocket pharmacy costs on branded medication adherence among patients with type 2 diabetes WS Bibeau, H Fu, AD Taylor, AYM Kwan Journal of managed care & specialty pharmacy 22 (11), 1338-1347, 2016 | 43 | 2016 |
| Factors associated with increased healthcare costs in Medicare Advantage patients with type 2 diabetes enrolled in a large representative health insurance plan in the US SL Slabaugh, BH Curtis, G Clore, H Fu, DP Schuster Journal of medical economics 18 (2), 106-112, 2015 | 43 | 2015 |
| Multicategory outcome weighted margin-based learning for estimating individualized treatment rules C Zhang, J Chen, H Fu, X He, YQ Zhao, Y Liu Statistica sinica 30, 1857, 2020 | 42 | 2020 |
| Estimating individualized treatment rules for ordinal treatments J Chen, H Fu, X He, MR Kosorok, Y Liu Biometrics 74 (3), 924-933, 2018 | 41 | 2018 |
| Closed loop control of physiological glucose C Yamei, FU Haoda, P Garhyan, AM Haidar, RE JONES, C Kovalchick, ... US Patent 11,901,060, 2024 | 37 | 2024 |
